Company profile: BioNTech
1.1 - Company Overview
Company description
- Provider of next-generation immunotherapies for cancer and infectious diseases, including mRNA-based drugs to encode antigens, neoantigens, cytokines and antibodies; engineered cell therapies (CAR-T and TCR); protein therapeutics such as antibodies, bispecifics and antibody-drug conjugates; and small-molecule immunomodulators. Also conducts clinical trials and advances a pipeline of investigational vaccines and immunotherapies.
Products and services
- Engineered Cell Therapies: Custom-engineered programs that modify T cells to recognize cancer-specific antigens, spanning CAR T constructs and TCR-based approaches for precise tumor targeting
- MRNA Therapies: mRNA-based therapeutics that deliver genetic instructions so cells produce antigens, neoantigens, cytokines, or antibodies, enabling oncology treatment and infectious disease prevention
- Protein-based Therapeutics: Bioconjugate-capable antibody products—covering monoclonal, bispecific, and antibody-drug conjugates—directed at diverse tumor types and select bacterial infections
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BioNTech
Sutro Biopharma
HQ: United States
Website
- Description: Provider of protein therapeutics leveraging OCFS and XpressCF cell-free protein synthesis, with an ADC pipeline: luveltamab tazevibulin (luvelta) targeting folate receptor alpha in clinical studies for platinum-resistant ovarian cancer; STRO-003 (ROR1-targeting) under a global licensing agreement with potential milestones and royalties; STRO-004 (tissue factor-targeting) planned for 2025 IND; plus sustainability efforts and a summer internship program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sutro Biopharma company profile →
Agenus
HQ: United States
Website
- Description: Provider of immunotherapies and vaccines for cancer and infectious diseases, advancing antibodies that activate antitumor immunity: botensilimab (CTLA-4; Phase 2 in melanoma, MSS colorectal and pancreatic cancers), balstilimab (PD-1; backbone for combinations), zalifrelimab (CTLA-4), AGEN2373 (CD137 agonist), AGEN1571 (ILT-2 antagonist), and an anti-ILT4 antagonist developed with pembrolizumab and chemotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agenus company profile →
Arcellx
HQ: United States
Website
- Description: Provider of immune cell therapies, including anitocabtagene autoleucel, a CAR-T targeting BCMA for relapsed or refractory multiple myeloma (Phase 1); ACLX-001, a controllable ARC-T cell therapy with a bivalent SparX protein targeting BCMA for relapsed or refractory multiple myeloma; and ACLX-002, an ARC-SparX therapy targeting CD123 for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arcellx company profile →
Calico Labs
HQ: United States
Website
- Description: Provider of research and development focused on the biology that controls aging and lifespan; a Google-sponsored company researching the challenges of aging and disease to diminish their effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calico Labs company profile →
Thallion Pharmaceuticals
HQ: Canada
Website
- Description: Provider of biotechnology-based pharmaceutical development in infectious disease and oncology, currently emphasizing treatment for Shigatoxin-producing E. coli (STEC) bacterial infections; leading product candidate is Shigamabs®, a dual antibody.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Thallion Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BioNTech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BioNTech
2.2 - Growth funds investing in similar companies to BioNTech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BioNTech
4.2 - Public trading comparable groups for BioNTech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →